Immunization with Bacillus spores expressing toxin a peptide repeats protects against infection with Clostridium difficile strains producing toxins A and B

Infection and Immunity

Volumn 79, Issue 6, 2011, Pages 2295-2302

  Permpoonpattana, Patima ^a   Hong, Huynh A ^a   Phetcharaburanin, Jutarop ^a   Huang, Jen Min ^a   Cook, Jenny ^a   Fairweather, Neil F ^b   Cutting, Simon M ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CLINDAMYCIN; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; POLYMER; PP108; PP142; PY79; UNCLASSIFIED DRUG; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL SPORE; BACTERIAL STRAIN; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS REACTION; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; TOXIN ANALYSIS; VACCINATION;

ANIMALS; ANTIBODIES, BACTERIAL; BACILLUS SUBTILIS; BACTERIAL PROTEINS; BACTERIAL TOXINS; BACTERIAL VACCINES; CLOSTRIDIUM DIFFICILE; CRICETINAE; CROSS PROTECTION; ENTEROCOLITIS, PSEUDOMEMBRANOUS; ENTEROTOXINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; MESOCRICETUS; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; SPORES, BACTERIAL; VACCINES, SYNTHETIC;

EID: 79959449569     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00130-11     Document Type: Article

References (44)

1. Aboudola, S., et al. 2003. Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A. Infect. Immun. 71:1608-1610.
2. Babcock, G. J., et al. 2006. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect. Immun. 74:6339-6347.
3. Barroso, L. A., S. Z. Wang, C. J. Phelps, J. L. Johnson, and T. D. Wilkins. 1990. Nucleotide sequence of Clostridium difficile toxin B gene. Nucleic Acids Res. 18:4004.
4. Buggy, B. P., R. Fekety, and J. Silva, Jr. 1987. Therapy of relapsing Clostridium difficile-associated diarrhea and colitis with the combination of vancomycin and rifampin. J. Clin. Gastroenterol. 9:155-159.
5. Carter, G. P., J. I. Rood, and D. Lyras. 2010. The role of toxin A and toxin B in Clostridium difficile-associated disease: past and present perspectives. Gut Microbes 1:58-64.
6. Dove, C. H., et al. 1990. Molecular characterization of the Clostridium difficile toxin A gene. Infect. Immun. 58:480-488.
7. Du, T., and M. J. Alfa. 2004. Translocation of Clostridium difficile toxin B across polarized Caco-2 cell monolayers is enhanced by toxin A. Can. J. Infect. Dis. 15:83-88.
8. Duc, L. H., H. A. Hong, N. Fairweather, E. Ricca, and S. M. Cutting. 2003. Bacterial spores as vaccine vehicles. Infect. Immun. 71:2810-2818.
9. Giannasca, P. J., and M. Warny. 2004. Active and passive immunization against Clostridium difficile diarrhea and colitis. Vaccine 22:848-856.
10. Goulding, D., et al. 2009. Distinctive profiles of infection and pathology in hamsters infected with Clostridium difficile strains 630 and B1. Infect. Immun. 77:5478-5485.
11. Harwood, C. R., and S. M. Cutting. 1990. Molecular biological methods for Bacillus. John Wiley & Sons Ltd., Chichester, England.
12. Hickson, M., et al. 2007. Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ 335:80.
13. Hoang, T. H., H. A. Hong, G. C. Clark, R. W. Titball, and S. M. Cutting. 2008. Recombinant Bacillus subtilis expressing the Clostridium perfringens alpha toxoid is a candidate orally delivered vaccine against necrotic enteritis. Infect. Immun. 76:5257-5265.
14. Hong, H. A., H. le Duc, and S. M. Cutting. 2005. The use of bacterial spore formers as probiotics. FEMS Microbiol. Rev. 29:813-835.
15. Huang, J. M., et al. 2010. Mucosal delivery of antigens using adsorption to bacterial spores. Vaccine 28:1021-1030.
16. Isticato, R., et al. 2001. Surface display of recombinant proteins on Bacillus subtilis spores. J. Bacteriol. 183:6294-6301.
17. Jank, T., T. Giesemann, and K. Aktories. 2007. Rho-glucosylating Clostridium difficile toxins A and B: new insights into structure and function. Glycobiology 17:15R-22R.
18. Jobe, B. A., A. Grasley, K. E. Deveney, C. W. Deveney, and B. C. Sheppard. 1995. Clostridium difficile colitis: an increasing hospital-acquired illness. Am. J. Surg. 169:480-483.
19. Johnson, S., W. D. Sypura, D. N. Gerding, S. L. Ewing, and E. N. Janoff. 1995. Selective neutralization of a bacterial enterotoxin by serum immunoglobulin A in response to mucosal disease. Infect. Immun. 63:3166-3173.
20. Kim, P. H., J. P. Iaconis, and R. D. Rolfe. 1987. Immunization of adult hamsters against Clostridium difficile-associated ileocecitis and transfer of protection to infant hamsters. Infect. Immun. 55:2984-2992.
21. Kink, J. A., and J. A. Williams. 1998. Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection. Infect. Immun. 66:2018-2025.
22. Kotloff, K. L., et al. 2001. Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults. Infect. Immun. 69:988-995.
23. Kuehne, S. A., et al. 2010. The role of toxin A and toxin B in Clostridium difficile infection. Nature 467:711-713.
24. Kyne, L., M. Warny, A. Qamar, and C. P. Kelly. 2000. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N. Engl. J. Med. 342:390-397.
25. Lawley, T. D., et al. 2009. Proteomic and genomic characterization of highly infectious Clostridium difficile 630 spores. J. Bacteriol. 191:5377-5386.
26. Leav, B. A., et al. 2010. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine 28:965-969.
27. Lowy, I., et al. 2010. Treatment with monoclonal antibodies against Clostridium difficile toxins. N. Engl. J. Med. 362:197-205.
28. Lyerly, D. M., H. C. Krivan, and T. D. Wilkins. 1988. Clostridium difficile: its disease and toxins. Clin. Microbiol. Rev. 1:1-18.
29. Lyerly, D. M., K. E. Saum, D. K. MacDonald, and T. D. Wilkins. 1985. Effects of Clostridium difficile toxins given intragastrically to animals. Infect. Immun. 47:349-352.
30. Lyras, D., et al. 2009. Toxin B is essential for virulence of Clostridium difficile. Nature 458:1176-1179.
31. Mauriello, E. M., et al. 2004. Display of heterologous antigens on the Bacillus subtilis spore coat using CotC as a fusion partner. Vaccine 22:1177-1187.
32. Rupnik, M., M. H. Wilcox, and D. N. Gerding. 2009. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat. Rev. Microbiol. 7:526-536.
33. Sambol, S. P., J. K. Tang, M. M. Merrigan, S. Johnson, and D. N. Gerding. 2001. Infection of hamsters with epidemiologically important strains of Clostridium difficile. J. Infect. Dis. 183:1760-1766.
34. Sauerborn, M., P. Leukel, and C. von Eichel-Streiber. 1997. The C-terminal ligand-binding domain of Clostridium difficile toxin A (TcdA) abrogates TcdA-specific binding to cells and prevents mouse lethality. FEMS Microbiol. Lett. 155:45-54.
35. Stubbe, H., J. Berdoz, J. P. Kraehenbuhl, and B. Corthesy. 2000. Polymeric IgA is superior to monomeric IgA and IgG carrying the same variable domain in preventing Clostridium difficile toxin A damaging of T84 monolayers. J. Immunol. 164:1952-1960.
36. Surawicz, C. M., et al. 2000. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin. Infect. Dis. 31:1012-1017.
37. Tam, N. K., et al. 2006. The intestinal life cycle of Bacillus subtilis and close relatives. J. Bacteriol. 188:2692-2700.
38. Torres, J., M. Camorlinga-Ponce, and O. Munoz. 1992. Sensitivity in culture of epithelial cells from rhesus monkey kidney and human colon carcinoma to toxins A and B from Clostridium difficile. Toxicon 30:419-426.
39. Torres, J. F., D. M. Lyerly, J. E. Hill, and T. P. Monath. 1995. Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters. Infect. Immun. 63:4619-4627.
40. von Eichel-Streiber, C., R. Laufenberg-Feldmann, S. Sartingen, J. Schulze, and M. Sauerborn. 1992. Comparative sequence analysis of the Clostridium difficile toxins A and B. Mol. Gen. Genet. 233:260-268.
41. von Eichel-Streiber, C., I. Warfolomeow, D. Knautz, M. Sauerborn, and U. Hadding. 1991. Morphological changes in adherent cells induced by Clostridium difficile toxins. Biochem. Soc. Trans. 19:1154-1160.
42. Voth, D. E., and J. D. Ballard. 2005. Clostridium difficile toxins: mechanism of action and role in disease. Clin. Microbiol. Rev. 18:247-263.
43. Ward, S. J., G. Douce, G. Dougan, and B. W. Wren. 1999. Local and systemic neutralizing antibody responses induced by intranasal immunization with the nontoxic binding domain of toxin A from Clostridium difficile. Infect. Immun. 67:5124-5132.
44. Ward, S. J., G. Douce, D. Figueiredo, G. Dougan, and B. W. Wren. 1999. Immunogenicity of a Salmonella typhimurium aroA aroD vaccine expressing a nontoxic domain of Clostridium difficile toxin A. Infect. Immun. 67:2145-2152.